Skip to content Skip to footer
Subscribe Now
NEWS

Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies

Shots: Harbour BioMed has entered into a multi-year, global strategic collaboration & license agreement with BMS to discover & develop next-generation multi-specific antibodies leveraging the Harbour Mice platform As per the deal, Harbour BioMed & BMS will jointly identify & advance multi-specific antibody programs, with Harbour eligible for $90M in total payments, ~$1.03B in development & commercial…
December 17, 2025

Read more

NEWS

Zealand Pharma Inks ~$2.5B Deal with OTR Therapeutics to Discover and Develop Metabolic Disease Therapies

Shots: Zealand Pharma has entered into a multi-program strategic collaboration & license agreement with OTR to discover & develop oral small molecules for metabolic diseases OTR & Zealand will jointly discover & develop multiple metabolic disease therapies, with OTR using its discovery platform to lead discovery & preclinical work while Zealand will handle global clinical…
December 11, 2025

Read more

NEWS

Formation Bio Licenses Lynk Pharmaceuticals’ LNK01006 to Expand its Immunology Pipeline

Shots: Lynk Pharmaceuticals has entered into an exclusive development & licensing agreement with Formation Bio, granting the latter worldwide rights to LNK01006 (excl. Greater China), a highly selective TYK2 inhibitor LNK01006 will be developed by Formation’s new subsidiary, Bleecker Bio, following recent US FDA IND clearance, with a P-I trial planned to start in the…
December 11, 2025

Read more

NEWS

Novartis and Relation Therapeutics Ink ~$1.75B Atopic Disease Target-Discovery Alliance

Shots: Relation has entered into a multi-program, strategic collaboration with Novartis to identify & advance novel targets for atopic diseases, leveraging Relation’s Lab-in-the-Loop platform As per the deal, Relation will lead patient-derived observational studies to create high-resolution functional cell atlases, while Novartis will secure global development & commercialization rights to any resulting targets In return,…
December 10, 2025

Read more

NEWS

Pfizer Collaborates with YaoPharma in a ~$2.1B Licensing Deal for YP05002

Shots: Pfizer has entered into an exclusive global collaboration & license agreement with YaoPharma for YP05002, a GLP-1 receptor agonist for chronic weight management As per the deal, YaoPharma will complete the ongoing P-I trial of YP05002 & grant Pfizer exclusive global rights for further development, manufacturing & commercialization, receiving $150M upfront & ~$1.935B in…
December 10, 2025

Read more

NEWS

Alexion (AstraZeneca) and Neurimmune Expand Alliance to Develop NI009 for AL Amyloidosis

Shots: Neurimmune has entered into an exclusive global collaboration & licensing deal with Alexion to develop NI009, a preclinical human mAb for the treatment of AL amyloidosis Alexion will obtain an exclusive global license to Neurimmune’s AL amyloidosis–targeting Abs, incl. NI009, with Neurimmune handling preclinical activities, early manufacturing & the FIH study, while Alexion will…
December 5, 2025

Read more

NEWS

Regeneron and Tessera Therapeutics Enter ~$275M Collaboration to Advance TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD)

Shots: Regeneron has entered into a global collaboration with Tessera Therapeutics to develop & commercialize TSRA-196 as a one-time gene editing treatment of AATD As per the deal, Tessera & Regeneron will equally share global development costs & potential future profits for TSRA-196. Tessera will receive $150M in upfront & equity investment plus $125M in near…
December 2, 2025

Read more

NEWS

Imugene Collaborates with JW Therapeutics to Advance onCARlytics and Carteyva Combination in Solid Tumours

Shots: Imugene has entered into a co-development collaboration with JW Therapeutics to evaluate Imugene's oncolytic virus CF33-CD19 (onCARlytics) & JW's Carteyva for pts with advanced solid tumors The company will jointly perform preclinical in vitro & in vivo studies & will advance the combination to a P-I investigator-initiated trial conducted exclusively at CAR-T clinical centers…
November 28, 2025

Read more

GSK and LTZ Therapeutics
NEWS

GSK Collaborates with LTZ Therapeutics to Advance Myeloid Cell Engager Therapies in Oncology

Shots: GSK has entered into a strategic research collaboration with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) in oncology, leveraging LTZ’s immune-engager platform Under the collaboration, GSK & LTZ aim to develop up to four MCE therapies for hematologic cancers & solid tumors, with GSK receiving an exclusive option to…
November 19, 2025

Read more

Load more